A detailed history of Swiss National Bank transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Swiss National Bank holds 159,152 shares of RARE stock, worth $7.23 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
159,152
Previous 145,852 9.12%
Holding current value
$7.23 Million
Previous $5.99 Million 47.48%
% of portfolio
0.01%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$40.21 - $59.36 $534,793 - $789,488
13,300 Added 9.12%
159,152 $8.84 Million
Q1 2024

May 07, 2024

BUY
$43.02 - $53.69 $184,986 - $230,867
4,300 Added 3.04%
145,852 $6.81 Million
Q4 2023

Feb 06, 2024

SELL
$31.73 - $49.19 $447,393 - $693,579
-14,100 Reduced 9.06%
141,552 $6.77 Million
Q3 2023

Nov 08, 2023

BUY
$34.92 - $46.66 $97,776 - $130,647
2,800 Added 1.83%
155,652 $5.55 Million
Q2 2023

Aug 09, 2023

BUY
$37.35 - $52.15 $339,885 - $474,565
9,100 Added 6.33%
152,852 $7.05 Million
Q1 2023

May 10, 2023

SELL
$36.99 - $48.71 $625,131 - $823,199
-16,900 Reduced 10.52%
143,752 $5.76 Million
Q4 2022

Feb 08, 2023

BUY
$33.72 - $46.33 $104,532 - $143,623
3,100 Added 1.97%
160,652 $7.44 Million
Q3 2022

Nov 09, 2022

BUY
$39.96 - $66.14 $91,908 - $152,122
2,300 Added 1.48%
157,552 $6.52 Million
Q2 2022

Aug 09, 2022

BUY
$45.8 - $85.4 $96,180 - $179,340
2,100 Added 1.37%
155,252 $9.26 Million
Q1 2022

May 09, 2022

BUY
$62.2 - $84.4 $702,860 - $953,720
11,300 Added 7.97%
153,152 $11.1 Million
Q4 2021

Feb 08, 2022

BUY
$73.71 - $87.86 $14,741 - $17,572
200 Added 0.14%
141,852 $11.9 Million
Q3 2021

Nov 08, 2021

BUY
$77.92 - $102.4 $116,880 - $153,600
1,500 Added 1.07%
141,652 $12.8 Million
Q2 2021

Aug 06, 2021

SELL
$92.19 - $115.71 $313,446 - $393,414
-3,400 Reduced 2.37%
140,152 $13.4 Million
Q1 2021

May 07, 2021

BUY
$106.9 - $167.73 $1.43 Million - $2.25 Million
13,400 Added 10.3%
143,552 $16.3 Million
Q4 2020

Feb 05, 2021

BUY
$84.4 - $177.39 $126,600 - $266,085
1,500 Added 1.17%
130,152 $18 Million
Q3 2020

Nov 09, 2020

BUY
$72.98 - $90.0 $430,582 - $531,000
5,900 Added 4.81%
128,652 $10.6 Million
Q2 2020

Aug 05, 2020

BUY
$46.91 - $78.22 $764,633 - $1.27 Million
16,300 Added 15.31%
122,752 $9.6 Million
Q1 2020

May 08, 2020

BUY
$33.8 - $62.9 $54,079 - $100,640
1,600 Added 1.53%
106,452 $4.73 Million
Q4 2019

Feb 06, 2020

BUY
$36.08 - $45.83 $72,160 - $91,660
2,000 Added 1.94%
104,852 $4.48 Million
Q3 2019

Nov 12, 2019

BUY
$42.5 - $63.11 $136,000 - $201,952
3,200 Added 3.21%
102,852 $4.4 Million
Q2 2019

Aug 02, 2019

BUY
$54.93 - $74.36 $76,902 - $104,104
1,400 Added 1.42%
99,652 $6.33 Million
Q1 2019

May 10, 2019

BUY
$39.87 - $69.36 $558,180 - $971,040
14,000 Added 16.62%
98,252 $6.82 Million
Q4 2018

Feb 13, 2019

BUY
$38.89 - $77.3 $85,558 - $170,060
2,200 Added 2.68%
84,252 $3.66 Million
Q2 2018

Aug 09, 2018

BUY
$48.54 - $85.31 $213,576 - $375,364
4,400 Added 5.67%
82,052 $6.31 Million
Q1 2018

May 04, 2018

BUY
$44.33 - $58.52 $341,341 - $450,604
7,700 Added 11.01%
77,652 $3.96 Million
Q4 2017

Feb 07, 2018

BUY
$43.54 - $57.32 $117,558 - $154,764
2,700 Added 4.01%
69,952 $3.24 Million
Q3 2017

Nov 03, 2017

BUY
$49.79 - $66.32 $3.35 Million - $4.46 Million
67,252
67,252 $3.58 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.18B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.